BridgeBio Pharma (BBIO) Net Income towards Common Stockholders (2018 - 2026)

BridgeBio Pharma has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$164.0 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$164.0 million, up 2.02% year-over-year; the trailing twelve-month figure through Mar 2026 was -$721.6 million (down 8.02% YoY), and the FY2025 annual result was -$724.9 million, down 35.31% from the prior year.
• Net Income towards Common Stockholders came in at -$164.0 million for Q1 2026 at BridgeBio Pharma, up from -$192.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$9.9 million in Q2 2022 to a low of -$265.0 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$164.0 million (2026), against an average of -$149.9 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 89.77% in 2022 and tumbled 1502.06% in 2023, its largest moves.
• BridgeBio Pharma's Net Income towards Common Stockholders stood at -$137.6 million in 2022, then decreased by 22.21% to -$168.1 million in 2023, then tumbled by 57.63% to -$265.0 million in 2024, then rose by 27.24% to -$192.9 million in 2025, then advanced by 14.94% to -$164.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$164.0 million (Q1 2026), -$192.9 million (Q4 2025), and -$182.7 million (Q3 2025), per Business Quant data.